Administration of antibodies specific for phosphorylated tau epitopes reduced tau pathology in transgenic NFT-bearing mice [75-77], and a tau aggregation inhibitor slowed AD’s progression in a phase II trial [78]. This evidence concerns the gene MAPT and Alzheimer disease.